Skin pigmentation in beauty

Half the products on a beauty counter now promise to do something about dark spots, and almost none of them are allowed to say the word they mean. Working out what the labels are actually claiming, and which ingredients have anything behind them, took me longer than it should have.

Why does it take so long for a product to change anything?

Because pigment has a whole journey to make before you see it, and a product can only interrupt part of it. The cycle runs in four stages:

1. UV radiation and signalling molecules inside the skin switch the melanocytes on.
2. Those cells synthesise melanin, both eumelanin, the brown to black pigment that absorbs UV, and pheomelanin, the yellow to red one that does not.
3. The pigment is packaged and passed to surrounding skin cells through the layers of the epidermis.
4. Epidermal renewal carries it to the surface, where you finally see it as colour.

Most actives work at stage one or three, so what is already sitting near the surface still has to shed on its own schedule. Four to twelve weeks is realistic. Anything promising a result in days is either exfoliating hard or lying. I have gone into the biology and the medical side of this in more detail in my piece on how skin pigmentation works and what goes wrong with it.

What are the labels actually allowed to say?

Less than you would think. Cosmetic claims in the UK and the EU have to meet common criteria set out in Regulation 655/2013, which require honesty, evidential support and no misleading impression, and the Advertising Standards Authority enforces the same principle in British advertising. A cream may say it targets the look of dark spots. It may not credibly promise to erase them, and it certainly cannot claim to treat a medical condition without becoming a medicine.

That is why the shelf vocabulary has drifted to brightening, evening and radiance. The wording is regulatory, not poetic.

Which actives have something behind them?

The niacinamide work is the one I keep coming back to. Hakozaki and colleagues, publishing in the British Journal of Dermatology in 2002, showed that niacinamide cut the transfer of pigment parcels from melanocytes to surrounding cells by 35 to 68 per cent in laboratory models, and that a 5 per cent formulation reduced hyperpigmentation in Japanese and Caucasian participants over four weeks. Twenty-odd years on, nothing sold over a counter has beaten it for the ratio of evidence to irritation.

How big is this market, and who is it really for?

Bigger than the beauty press admits and harder to size than the press releases suggest. Commercial forecasts for 2026 range from roughly 9 billion to 19 billion US dollars depending on whether the analyst counts brightening serums, skin-lightening creams or both, which is a spread wide enough to treat every single figure with suspicion. What the reports agree on is geography: Asia Pacific takes the majority of revenue, at over half by most estimates.

That gap between “even tone” and “lighten skin” is not just marketing language. It is the reason regulators keep intercepting illegal creams, and the reason I would rather talk about protecting skin than changing its colour.

Why testing across skin types is the part nobody sees

An active that behaves beautifully on one skin type can do very little, or too much, on another. Phenocell, a preclinical contract research organisation in Grasse, reproduces melanocytes in vitro from induced pluripotent stem cells, and supplies them for Caucasian, Asian and African skin types along with keratinocytes and sebocytes. Its platform runs tests for both pro-pigmenting and de-pigmenting actives, for dermatology as well as cosmetics.

The practical value is consistency. Donated cells vary from batch to batch and from donor to donor, which makes results hard to compare. Reprogrammed cells give researchers the same starting point every time, across phototypes, which is exactly what has been missing from an industry that has historically tested on a narrow slice of skin and generalised from it.

What I do on set, when treatment is not the point

Sometimes the job is coverage, not correction, and that is a colour theory problem rather than a skincare one. Brown patches need warmth underneath, so a peach or orange corrector on deeper tones and a peach-toned one on fair skin will neutralise far better than piling on concealer, which usually turns grey. Thin layers, pressed rather than swept, and set only where it needs to stay.

None of that treats anything. It just buys you a good day while the slower work of sun protection and one well-chosen active does its thing over the following months.

Updated 11 August 2026. General information on cosmetic products, not medical advice. Persistent or changing pigmentation should be assessed by a GP or dermatologist, and prescription treatments should only be used under supervision.

Sources: Hakozaki T et al., British Journal of Dermatology, 2002; Regulation (EU) 655/2013 on common criteria for cosmetic claims; Regulation (EU) 2024/996 on kojic acid; Regulation (EC) 1223/2009, Annex II, on hydroquinone; commercial market forecasts published 2025 and 2026, figures diverging by source; Phenocell company information on iPSC-derived skin cells.